Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tenidap - Pfizer

Drug Profile

Tenidap - Pfizer

Alternative Names: CP 66248; CP 66248 2; Enable; Enablex® - Rheumatoid arthritis; Kenida®; Reumaten; Tenedac

Latest Information Update: 25 Mar 1998

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Pfizer; Roerig Farmaceutici
  • Class Anti-inflammatories; Antirheumatics; Indoles
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Rheumatoid arthritis
  • Discontinued HIV infections; Osteoarthritis

Most Recent Events

  • 25 Mar 1998 Discontinued-Preregistration for Osteoarthritis in USA (PO)
  • 30 Jan 1998 Discontinued-I for HIV infections treatment in USA (Unknown route)
  • 05 Dec 1997 Data have been added to the Therapeutic Trials and Adverse Events sections
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top